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Lung cancer has the second highest cancer incidence, second only to prostate cancer in men and
breast cancer in women. Furthermore, more cancer deaths are attributable to lung cancer than any other cancer for
both genders. There is a high public health need for effective secondary prevention in the form of early detection
and early treatment, complementary to smoking cessation efforts. The U.S. National Lung Screening Trial (NLST)
demonstrated that non-small cell lung cancer (NSCLC) mortality can be reduced by 20% through a program of
annual CT screening in high-risk individuals. However, CT screening regimens and adherence vary, potentially
impacting the lung cancer mortality benefit.
The mortality benefit attributable to a program of CT screening is largely determined by the natural history of lung
cancer progression. Tumor doubling times and the maximum tumor size at which a NSCLC would be curable by
early detection (cure threshold) are key factors. In this talk, I will address novel statistical methodology used to
estimate parameters governing a stochastic model of the natural history of lung cancer. We estimate the median
tumor size at cure threshold among the most aggressive NSCLCs to be between 10-15 mm. We demonstrate
consistency of our model with tumor size and stage data from distinct lung screening trials, namely, the Mayo Lung
Project, the Mayo CT study and the NLST, in addition to data from SEER, the national cancer registry and highlight
key differences between men and women. The majority of NSCLCs in the NLST were treated at tumor sizes greater
than our median cure threshold estimates, consistent with the modest 20% mortality reduction attributable to CT
screening observed in the NLST. These results highlight the strong need for novel classification technology that can
better distinguish and treat the most aggressive NSCLCs when they are small (i.e. 5-15mm).
This talk will also discuss the model’s consistency with the recently announced European NELSON lung screening
trial results (October 2018). I will also discuss how novel DNA sequencing technologies may be incorporated into a
lung screening regimen in order to improve outcomes.
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